Objectives. To estimate the incidence rate and prevalence of idiopathic inflammatory myopathies (IIMs) in Sweden across clinical subgroups, age, sex, educational level and place of residence and to assess the robustness of register-based case definitions.
Introduction
Idiopathic inflammatory myopathies (IIMs) are rare rheumatic muscle diseases encompassing a heterogeneous group of diseases most often classified as PM, DM, JDM and sporadic IBM [1] .
Incidence and prevalence estimates of IIM vary greatly across studies ranging from 1.2 to 66 new cases of IIM per 1 000 000 person-years (py) [25] , and it has been suggested that between 2.9 and 34 individuals per 100 000 suffer from the disease (supplementary Table S1 , available at Rheumatology Online) [68] . By studying the occurrence of myositis and how it varies with genetic and environmental factors, important clues to its aetiology can be revealed.
It has been reported that PM and DM are more common in women [1, 7, 9] whereas IBM is more common in men [10, 11] , suggesting that sex hormones may have a role in the pathogenesis. Some studies have presented evidence of seasonal variation [12, 13] and spatial clustering [9, 14] in IIM incidence, highlighting that environmental factors may play a role in disease development. Little is known about whether socioeconomic risk factors are associated with IIM, as has been observed in other diseases such as RA [15] .
The wide range of reported incidence and prevalence estimates may be due to differences in genetic and/or environmental factors, but it may also be due to differences in study design and methodology. The highest estimates are noted in register based studies where cases are defined using administrative codes [2, 6, 16, 17] , thus potentially overestimating the true incidence or prevalence. The lowest estimates are found in studies where cases are defined using classification criteria and biopsy findings [4, 8, 13, 18] , thus potentially underestimating the true incidence/prevalence. Where the true occurrence lies is still uncertain.
In order to further our understanding of disease aetiology and to produce robust and current estimates of the incidence and prevalence of IIM, we set out to study the occurrence of IIM in a nationwide setting, using Swedish national population registers. We also investigated how the occurrence varied with age, sex and IIM subgroups, as well as how incidence varied by level of education and place of residence.
Methods

Swedish national health care system
The Swedish health care system allows universal access to healthcare and is tax funded, and prescription drugs are free of charge over a threshold of SEK 2200. Adult IIM patients are generally treated by specialists at rheumatology or neurology clinics but in some regions/ hospitals, internal medicine and dermatology units are responsible for their care. Juvenile cases are treated at paediatric clinics until they turn 18 years old. We used the unique personal identification number given to each Swedish resident [19] , which allows identification of individuals in different registers over time, and enables us to link different national health care registers, demographics and census databases, the migration office and quality of care registers.
Included registers
The National Patient Register (NPR; 19642012) contains information on clinic, main and contributory diagnosis for each inpatient visit with national and virtually complete coverage from 1987. It includes non-primary care outpatient visits from 2001. The outpatient component covers $87% of all somatic care visits and the majority of missing visits were due to lack of reporting from private care givers [20] . Main and contributory diagnoses are assigned by the treating physician at each visit using International Classification of Disease (ICD) codes (ICD10 since 1997).
The Swedish Quality of care Register (SRQ; 19952012) includes patients seen in rheumatology clinics with rheumatic diseases (including IIM) since 1995 [21] , and lists date of diagnosis, variables on disease activity and treatment for each patient. SRQ includes specific IIM sub-diagnoses: PM, DM, IBM, JDM and unspecific myositis.
The Prescribed Drug Register (200512) lists all prescribed drugs dispensed at pharmacies in Sweden since July 2005. Relevant treatments (DMARDs and prednisolone) were identified using anatomical therapeutic chemical classification codes (supplementary Table S2 , available at Rheumatology Online). The Total Population Register contains county of residence and migration status as well as census numbers for the whole Swedish population as of 31 December for each year. The longitudinal integration database for health insurance and labour market studies (LISA) integrates information from the labour market, social and educational sectors and is updated yearly.
Study population
All individuals with one or more visits in the NPR with an ICD code (M33.0, M33.1, M33.2, G72.4, M60.8 and M60.9) or SRQ visit indicating IIM were included in the study as possible IIM cases. As data from the NPR were available through 2012 at the time of linkage, 2011 was used as last year of entry to allow subsequent follow-up time for a second visit.
Defining IIM
Experts in the field were consulted to determine which ICD codes are used in the clinic for IIM. ICD codes M60.8 and M60.9 were most commonly used in the diagnostic work-up when IIM was suspected during initial evaluation and before a definite diagnosis was made. Hence, these codes were used in sensitivity analyses only. Patients with IIM undergoing investigation were not included unless an ICD-code included in the study was registered in the National Patient Register or the patient was registered in SRQ.
Incidence case definition
For incident cases a first ever visit indicating IIM between 2007 and 2011 was defined as the index date. The incidence liberal case definition required one or more specialist visits while the base case definition required two or more specialist visits (rheumatology, neurology, internal medicine, dermatology and paediatric) in the patient register or SRQ, with a subsequent visit occurring 112 months after the index date. The strict definition additionally required one or more dispensings of prednisolone or DMARD within 12 months of index date (supplementary Table S3 , available at Rheumatology Online).
To assess stability of case definitions, a number of alternative case definitions were also tested. Time allowed between the first and subsequent visit was varied (6 and www.rheumatology.oxfordjournals.org 24 months). Cases that dispensed immunosuppressive medication >6 or >12 months prior to the index date or were identified through contributory diagnoses only were excluded.
Prevalence case definition
The prevalence base case definition required two or more specialist visits or SRQ registration indicating IIM with a first registered visit before 1 January 2012. To assess robustness of this case definition, a liberal definition (one or more specialist visits) and a strict definition (base case + dispensation of prednisolone or DMARDs) were also used to estimate prevalence. Incident cases had to be registered (alive and not migrated) the whole index year and prevalent cases had to be registered on 31 December 2011 to be included in the study.
Clinical sub-diagnosis
IIM sub-diagnoses were identified using M33.1 and M33.9 for DM, M33.2 for PM, M33.0 for JDM and G72.4 for IBM. There is no specific ICD code corresponding to IBM but G72.4 was primarily used for IBM patients registered in SRQ, where diagnosis is assigned by the name of disease (and not the ICD code). To validate the different ICD codes used to assign clinical sub-diagnosis, positive predictive values were calculated, using SRQ as the gold standard for prevalent cases who were also registered in SRQ. All included ICD codes had a positive predictive value >90% except M33.2 (PM) and M33.9 (DM), 83% and 57%, respectively (supplementary Table S4 , available at Rheumatology Online).
Because some individuals retrieved different ICD codes at different visits, clinical sub-diagnosis was set by the following priority: SRQ diagnosis; last diagnosis at a rheumatology clinic; last diagnosis at another specialist clinic. Cases were assigned myositis unspecified if they were assigned this diagnosis in SRQ. Patients with their first specialist visit before the age of 18 years were classified as JDM.
Covariates
Date of birth was used to calculate age. Municipality was defined as urban if the population density was >400/km 2 and had more than 1000 inhabitants using similar methods as in a previous study [9] . Education was categorized into three levels: 49, 1012 and 512 years. Education was only collected on residents <75 years of age. Because cases under 30 years of age may not have finished their education, analyses on education level were restricted to subjects aged 3074 years.
Statistical analyses
Overall incidence per 1 000 000 py between 2007 and 2011 was estimated and age-and sex-standardized incidence rates were calculated by education level and place of residence. Confidence intervals were estimated assuming a Poisson distribution for incidence rates and a Binomial distribution for prevalence and estimated using the exact method [2224] . County heat maps were produced using Statistics Sweden's web-based tool Statistikatlasen [25] . Prevalence per 100 000 was estimated using the entire Swedish population as the denominator. Prevalence and incidence estimates were stratified by age, sex, education level and place of residence. SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 3.20 (R Foundation for Statistical Computing, Vienna, Austria) were used in the analyses. Ethical approval was granted by the Regional Ethics Committee, Karolinska Institutet, Stockholm, Sweden and, as all data was completely anonymized, no patient consent form was needed.
Results
The entire Swedish population on 31 December 2011 was 9 482 855, and 7 563 649 were 518 years of age [26] .
Incidence rates
Between 2007 and 2011, 856 first ever visits indicating IIM were identified, 716 listed at least one specialist visit and 558 had 52 visits. A consecutive visit was listed within 12 months but >1 month apart for 522 individuals. Dispensation of DMARDs or prednisolone within 12 months of index date was registered in 490 cases. Between 145 and 180 new cases were identified per year and no time trend was observed.
The average incidence rates per 1 000 000 py were 15 (95% CI: 14, 17) for the liberal definition, 11 (95% CI: 10, 12) for the base case and 10 (95% CI: 9.6, 11) for the strict definition. Fifty-seven per cent of cases were female and the average age at diagnosis was 57 years and did not differ by case definition (Table 1) . For JDM, 66% were female and the mean age at diagnosis was 10 years when using the base case definition.
Using the base case definition, overall incidence rates were 13 (95% CI: 11, 14) for women and 9.7 (95% CI: 8.1, 11) per 1 000 000 py for men. The incidence generally increased with age for both sexes with a peak at 5079 years of age with the highest incidence rate in the 7079 year age group for both women and men (Table 2 ). The estimates grouped by age and sex remained stable when case definitions were changed (Fig. 1A) . Incidence rates were higher for women for all subgroups except for IBM. PM had the highest incidence rates, 6.5 and 4.9 per 1 000 000 py for women and men, respectively (Table 2) .
Age-and sex-standardized incidence rates were similar across educational levels and when comparing urban to rural municipalities (Table 3) . A three-fold variation was observed for the 21 different Swedish counties (supplementary Table 5 , available at Rheumatology Online) but no north to south gradient was observed for overall IIM or DM incidence rates for the different counties (Fig. 2) .
Sensitivity analysis
The number of identified cases was similar when case definitions with other inclusion criteria were used (supplementary Fig. S1 , available at Rheumatology Online). When ICD codes M60.8 and M60.9 were included, the number of identified cases with 51 visit at any non-primary care clinic increased to 2902, of which 59% had 51 visit at a specialist clinic and 22% had 52 visits, which corresponded to incidence rates of 62, 36 and 14 per 1 000 000, respectively. Rates more than doubled for age-and sex-stratified groups when requiring only one specialist visit (supplementary Fig. S2 , available at Rheumatology Online).
Prevalence
A total of 2310 unique individuals were identified with 51 IIM visit between 2001 and 2012. The estimated prevalence on 1 January 2012 was 14 (95% CI: 13, 14) per 100 000 for the base case definition and 91% had >3 specialist visits indicating IIM. Age, sex and educational level were similar across case definitions; 61% were women, mean age was 5960 years and 39% had an educational level of 912 years (Table 4 ). The prevalence was 17 and 11 per 100 000 for women and men, respectively, and the prevalence was higher in women for all age groups except for ages 09 and 80+ (Table 2) . Prevalence increased with age and peaked at the age of 7079 years. Small differences were observed when applying the liberal and base case definitions (Fig. 1B) .
Discussion
Using nationwide, population-based registers including Sweden's almost 10 million citizens, making it one of the largest studies on adult and juvenile IIM occurrence to date, we estimated an overall IIM incidence rate of 11 per 1000 000 py and a prevalence of 14 per 100 000. Incidence rates increased with age and peaked at 5079 years of age.
With respect to place of residence, no differences were observed in incidence rates when comparing rural to urban areas, unlike what has been suggested previously [9] . Also, no obvious north to south gradient was observed in age-and sex-standardized incidence rates for IIM overall or DM as has been observed in previous studies from the USA and Europe [27, 28] . This may be due to the location of Sweden between latitudes 55 and 68 N, making it one of Europe's most northern countries compared with mainland USA, which is situated between 25 and 49 N. Furthermore, the number of identified cases for some counties was low, making these estimates uncertain.
To our knowledge, a difference in IIM incidence for different levels of education has not previously been investigated. However, no differences were observed between the groups, unlike what has been shown in RA [15, 21] .
Compared with results from previous studies, our incidence estimate, 11/1000 000 py, is higher than the incidence reported by a recent study from Australia as well as a recent meta-analysis, which both estimated the incidence to 8.0/1 000 000 [29, 30] . Local hospital studies from Sweden and the USA have also presented lower estimates compared with our study, 7.6 and 5.5 per 1000 000 py, respectively [3, 31] . These studies have required cases to be biopsy-verified, which could result in an underestimation of the true incidence rate. Our estimate is lower compared with two studies using large medical claims databases from the USA, which estimated an incidence of 43 and 66 per 1 000 000 py [2, 16] . These high estimates are comparable to estimates in our sensitivity analysis where incidence was increased by up to 200% when M60.89 codes were used to identify IIM patients. In clinics these codes are mainly used in the work-up before a definite diagnosis is established as confirmed in discussion with experts in the Swedish myositis network.
Incidence of IIM is commonly said to be bimodal, with a first peak in juvenile cases and a second peak in older patients. We did not find a first peak for juvenile cases; instead incidence rates generally increased with age with a peak in the 5079 years age groups, which is at a higher age than previously reported from Taiwan [32] but similar to studies from the USA and Australia [2, 16, 30] . Incidence rates under 18 years varied between 3.2 and 3.4 per 1 000 000 py (Table 2) , which is higher than what has been reported for juvenile IIM in Sweden and Finland [33, 34] while being similar and slightly lower compared with two studies from the USA [35, 36] .
Regarding prevalence, our estimate is similar to that reported by a recent meta-analysis, which estimated an IIM prevalence of 14/100 000 [29] . Two recent regional population-based studies from Norway [7, 11] presented Incidence rates per 1 000 000 person years and prevalence per 100 000. Incident cases defined using the incident base case definition (first ever visit indicating IIM between 2007 and 2011 with a consecutive visit within 1 year, but >30 days apart or registration in the Swedish Rheumatology Quality Register (SRQ). Prevalent cases defined using the prevalence base case definition (52 visits indicating IIM before 1 January 2012).
FIG. 1
Annual incidence rates and prevalence of idiopathic inflammatory myopathies by age and gender (A) Mean annual incidence rates per 1 000 000 person years and (B) prevalence per 100 000 of idiopathic inflammatory myositis (IIM) stratified by age and sex for three case definitions. Liberal: first ever specialist visit (visits at rheumatology, neurology, internal medicine, dermatology and paediatric clinics) or SRQ listing; Base case: Liberal plus one consecutive visit within 1 year following index date (but at least 30 days apart) or SRQ registration; Strict: Base case plus dispensation of DMARDs or glucocorticoids ±12 months from index date or SRQ registration.
a combined prevalence for PM, DM and IBM of 11/100 000 as well as one regional study from Sweden [37] while studies from the USA and Canada using administrative health claims databases have estimated prevalence higher than in our study, ranging between 17 and 34 per 100 000 [2, 6, 9, 16]. When we examined the clinical diagnoses, the incidence of IBM was less than half of what has previously been reported in Sweden [38] . The prevalence of IBM is lower compared with what has been estimated in Norway [11] but higher when comparing with estimates from the Netherlands [39] . Furthermore, some investigators report that up to 30% of IIM patients have IBM [40] . From SRQ, where approximately one-third of identified patients are registered, we could estimate the proportion of prevalent IBM patients as 15% compared with 7% for when using the ICD codes. Because no specific ICD code is available for IBM, the code for PM is commonly used in clinical practice and it is likely that we underestimate the frequency of IBM in our study. Another more recently identified subgroup of IIM, also lacking a separate ICD code, is the so-called autoimmune necrotizing myopathy including an autoimmune myopathy associated with statin use. This subgroup is likely to have been included among the PM cases, but the frequency cannot be determined through the register based analysis whereas the more common statin myopathy would not have been included in our IIM cohort. The occurrence of the sub-diagnoses is likely to be more valid for DM and JDM because they have distinct ICD10 codes and the frequency of these diagnoses were comparable between the SRQ and ICD codes (supplementary Table S6 , available at Rheumatology Online).
Previous studies include different patient populations depending on which sub-diagnoses were investigated and whether only adult cases were studied. Some have only looked at PM and DM [41] while others have included interstitial myositis in their overall estimates [2, 16] . Studies from Australia [30, 42] only included muscle biopsy verified IIM patients, which might lead to underestimation as not all patients are subject to muscle biopsy or present typical biopsy findings. Furthermore, including patients who fulfil defined classification criteria will strengthen the specificity of diagnosis but there is a risk of underestimation due to missing data.
We did not review medical records of all identified patients to ascertain diagnosis, which may have led to some misclassification. However, using diagnostic criteria with retrospective chart review may underestimate the true incidence and prevalence due to missing data, as most criteria require several investigations, which in the clinical context may not always be performed or information may be missing in patient records. We chose to instead use an algorithm that tries to mimic patients' flow through the health care system to identify patients. Consequently, estimates presented in this study reflect all patients living in Sweden seeking care for IIM and receiving a diagnosis from a specialist. Register-based case identification estimates vary largely depending on the algorithm used to define cases. A too lenient definition may include falsepositive cases while stricter definitions may exclude true cases. A transparent case definition is therefore of great importance when using such methods. In this study we present results from three different case definitions as well as a sensitivity analysis, and despite the definitions being varied the number of included cases remained stable regardless of definition.
Our use of population-based registers covering Sweden's whole population of almost 10 million residents resulted in robust estimates of IIM occurrence. These registers have nearly complete coverage for patients who have been hospitalized or have had specialist www.rheumatology.oxfordjournals.org outpatient clinic visits during the time period for our study [20] . Similar methods have used Swedish national and quality of care registers to produce robust estimates of the incidence and prevalence of other rheumatic diseases [21, 43] . However, because the Swedish population is mainly Caucasian, our results may not be generalizable to other ethnicities.
In conclusion, we observed stable incidence and prevalence estimates across three case definitions of IIM. The incidence rate was stable over the study period and there   FIG. 2 Heat map of incidence rates by Sweden's 21 counties Difference (%) in age and sex standardized incidence rates compared with overall incidence rate for idiopathic inflammatory myositis (left) and DM (right) for Sweden's 21 counties. Sweden is located between 55 and 68 N, and 11 and 19 E.
were no variations explained by levels of education or geographical regions. We show that available registers can be used to robustly identify incident and prevalent IIM cases, and serve as a unique and valuable resource to better understand this enigmatic disease. The challenges to studying IIM due to its rarity can be overcome using these comprehensive and nationwide data, which will be of great importance in moving research on IIM forward. 
